

Jason S Knight

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7657979/jason-s-knight-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers

7,739
citations

41
h-index

87
g-index

109
ext. papers

10,008
ext. citations

7.7
avg, IF

6.24
L-index

#	Paper	IF	Citations
102	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.. <i>Seminars in Immunopathology</i> , 2022 , 1	12	5
101	Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series.. <i>Pediatric Rheumatology</i> , 2022 , 20, 17	3.5	0
100	Circulating Calprotectin as a Predictive and Severity Biomarker in Patients with COVID-19. <i>Diagnostics</i> , 2022 , 12, 1324	3.8	1
99	SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. <i>Viruses</i> , 2021 , 13,	6.2	10
98	The intersection of COVID-19 and autoimmunity. <i>Journal of Clinical Investigation</i> , 2021 ,	15.9	22
97	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021 , 61, 64	3	
96	Defibrotide inhibits antiphospholipid antibody-mediated NET formation and venous thrombosis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	1
95	Understanding the Pathophysiology of Thrombotic APS through Animal Models. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
94	Endoplasmic reticulum stress sensor IRE1 β propels neutrophil hyperactivity in lupus. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	7
93	Autoantibodies stabilize neutrophil extracellular traps in COVID-19 2021 ,		5
92	Patients with COVID-19: in the dark-NETs of neutrophils. <i>Cell Death and Differentiation</i> , 2021 , 28, 3125-3129		61
91	Autoantibodies stabilize neutrophil extracellular traps in COVID-19. <i>JCI Insight</i> , 2021 , 6,	9.9	18
90	The IRE1 β Stress Signaling Axis Is a Key Regulator of Neutrophil Antimicrobial Effector Function. <i>Journal of Immunology</i> , 2021 ,	5.3	1
89	Neutrophil extracellular traps and thrombosis in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 446-453	5.1	99
88	Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. <i>Journal of Leukocyte Biology</i> , 2021 , 109, 67-72	6.5	60
87	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021 , 48, 541-547	4.1	4
86	Endothelial cell-activating antibodies in COVID-19 2021 ,		13

85 Tissue injury *The biology* **2021**, 271-285

84 Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. *Scientific Reports*, **2021**, 11, 1580 4.9 81

83 Antineutrophil properties of natural gingerols in models of lupus. *JCI Insight*, **2021**, 6, 9.9 5

82 Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide **2021**, 2

81 Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. *Expert Review of Clinical Immunology*, **2021**, 17, 395-406 5.1 1

80 The interplay between neutrophils, complement, and microthrombi in COVID-19. *Best Practice and Research in Clinical Rheumatology*, **2021**, 35, 101661 5.3 18

79 Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. *JCI Insight*, **2021**, 6, 9.9 7

78 COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).. *Lupus*, **2021**, 9612033211062523 2.6 3

77 Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. *Science Translational Medicine*, **2020**, 12, 17.5 277

76 Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome. *BMJ Case Reports*, **2020**, 13, 0.9 3

75 Neutrophil extracellular traps in COVID-19. *JCI Insight*, **2020**, 5, 9.9 575

74 New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm. *JCI Insight*, **2020**, 5, 9.9 28

73 Neutrophil extracellular traps and thrombosis in COVID-19 **2020**, 41

72 Neutrophil calprotectin identifies severe pulmonary disease in COVID-19 **2020**, 10

71 Prothrombotic antiphospholipid antibodies in COVID-19 **2020**, 25

70 Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients **2020**, 10

69 The role of neutrophil extracellular traps and TLR signaling in skeletal muscle ischemia reperfusion injury. *FASEB Journal*, **2020**, 34, 15753-15770 0.9 4

68 Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. *Arthritis Care and Research*, **2020**, 4.7 13

67	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776	2.6	12
66	Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2020 , 72, 2130-2135	9.5	22
65	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	795
64	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020 , 29, 1571-1593	2.6	27
63	NETs in APS: Current Knowledge and Future Perspectives. <i>Current Rheumatology Reports</i> , 2020 , 22, 67	4.9	10
62	Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by α Integrin Mac-1. <i>Arthritis and Rheumatology</i> , 2020 , 72, 114-124	9.5	27
61	Treatment of thrombotic antiphospholipid syndrome in adults and children. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 215-227	5.3	2
60	Antiphospholipid syndrome: a clinical perspective. <i>Chinese Medical Journal</i> , 2020 , 133, 929-940	2.9	11
59	Antimicrobial Microwebs of DNA-Histone Inspired from Neutrophil Extracellular Traps. <i>Advanced Materials</i> , 2019 , 31, e1807436	24	17
58	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 464-468	5.3	38
57	Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. <i>Nature Communications</i> , 2019 , 10, 1916	17.4	92
56	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2069-2080	15.4	4
55	Extracellular Trap-Mimicking DNA-Histone Mesostructures Synergistically Activate Dendritic Cells. <i>Advanced Healthcare Materials</i> , 2019 , 8, e1900926	10.1	6
54	3005 Integrin Mac-1 Potentiates Neutrophil Adhesion and NET Release in Antiphospholipid Syndrome. <i>Journal of Clinical and Translational Science</i> , 2019 , 3, 14-14	0.4	78
53	Disruption of Neutrophil Extracellular Traps (NETs) Links Mechanical Strain to Post-traumatic Inflammation. <i>Frontiers in Immunology</i> , 2019 , 10, 2148	8.4	10
52	Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1 β -driven venous thrombosis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2872-2877	15.9	52
51	Pediatric antiphospholipid syndrome. <i>European Journal of Rheumatology</i> , 2019 , 1-10	1.7	12
50	Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 231-240	5.3	6

49	To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps. <i>Cell Death and Differentiation</i> , 2019 , 26, 395-408	12.7	185
48	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23
47	Tenosynovitis Revealed by Fungal Culture in a Patient Treated with Infliximab. <i>Journal of Rheumatology</i> , 2018 , 45, 284-285	4.1	3
46	Myeloid-Specific Deletion of Peptidylarginine Deiminase 4 Mitigates Atherosclerosis. <i>Frontiers in Immunology</i> , 2018 , 9, 1680	8.4	48
45	Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction. <i>Frontiers in Immunology</i> , 2018 , 9, 1322	8.4	13
44	Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils. <i>Clinical Immunology</i> , 2018 , 196, 110-116	9	17
43	Neutrophil extracellular traps (NETs) are increased in the alveolar spaces of patients with ventilator-associated pneumonia. <i>Critical Care</i> , 2018 , 22, 358	10.8	66
42	DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. <i>Nature Communications</i> , 2017 , 8, 14252	17.4	49
41	Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 450-457	2.4	46
40	Antiphospholipid syndrome: an update for clinicians and scientists. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 458-466	5.3	10
39	A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia. <i>Arthritis Care and Research</i> , 2017 , 69, 1253-1259	4.7	4
38	Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice. <i>Scientific Reports</i> , 2017 , 7, 14360	4.9	18
37	In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 655-667	9.5	117
36	Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. <i>JCI Insight</i> , 2017 , 2,	9.9	43
35	Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated autoimmunity. <i>Rheumatology</i> , 2017 , 56, 638-643	3.9	34
34	Response to: Monocyte type I interferon signature in antiphospholipid syndrome is related to pro-inflammatory monocyte subsets, hydroxychloroquine and statin use by van den Hoogen et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e82	2.4	1
33	Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. <i>Nature Medicine</i> , 2016 , 22, 146-53	50.5	721
32	Intercellular Interactions as Regulators of NETosis. <i>Frontiers in Immunology</i> , 2016 , 7, 453	8.4	36

31	Treatment of catastrophic antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 218-233	5.3	51
30	Reply. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1321-2	9.5	2
29	Psgl-1 Deficiency is Protective against Stroke in a Murine Model of Lupus. <i>Scientific Reports</i> , 2016 , 6, 28997	4.9	10
28	Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies. <i>Lupus Science and Medicine</i> , 2016 , 3, e000134	4.6	60
27	Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival. <i>Lupus Science and Medicine</i> , 2015 , 2, e000117	4.6	40
26	Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2199-206	2.4	244
25	Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2990-3003	9.5	193
24	Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases?. <i>World Journal of Cardiology</i> , 2015 , 7, 829-42	2.1	45
23	Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 1337-44	8.3	55
22	Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy. <i>Lupus Science and Medicine</i> , 2014 , 1, e000051	4.6	10
21	Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. <i>Circulation Research</i> , 2014 , 114, 947-56	15.7	250
20	Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. <i>Journal of Immunology</i> , 2014 , 192, 906-18	5.3	62
19	Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2532-2544	9.5	134
18	Cardiovascular disease in lupus: insights and updates. <i>Current Opinion in Rheumatology</i> , 2013 , 25, 597-605	5.3	63
17	NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2013 , 5, 178ra40	17.5	726
16	Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2981-93	15.9	263
15	Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. <i>Frontiers in Immunology</i> , 2012 , 3, 380	8.4	122
14	Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. <i>Journal of Immunology</i> , 2012 , 188, 3522-31	5.3	327

13	Lupus neutrophils: UNETU gain in understanding lupus pathogenesis. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 441-50	5.3	132
12	Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3354-62	2.2	152
11	Nm23-H1 modulates the activity of the guanine exchange factor Dbl-1. <i>International Journal of Cancer</i> , 2008 , 123, 500-10	7.5	37
10	Eighty-Five Cases of Lymphoma in a Solid Organ Transplant (SOT) Population: Risk, Treatment, and Histologic Subtype.. <i>Blood</i> , 2007 , 110, 1367-1367	2.2	
9	EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. <i>PLoS Pathogens</i> , 2006 , 2, e116	7.6	150
8	SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. <i>Molecular and Cellular Biology</i> , 2005 , 25, 1749-63	4.8	67
7	Regulation of matrix metalloproteinase 9 expression by Epstein-Barr virus nuclear antigen 3C and the suppressor of metastasis Nm23-H1. <i>Journal of Virology</i> , 2005 , 79, 9714-24	6.6	32
6	Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 18562-6	11.5	128
5	A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. <i>Journal of Virology</i> , 2004 , 78, 12857-67	6.6	41
4	Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. <i>Journal of Virology</i> , 2004 , 78, 1981-91	6.6	65
3	Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. <i>Journal of Virology</i> , 2003 , 77, 4261-72	6.6	108
2	The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter. <i>Journal of Biological Chemistry</i> , 2001 , 276, 22971-8	5.4	91
1	The bicyclomycin sensitivities of 38 bicyclomycin-resistant mutants of transcription termination protein rho and the location of their mutations support a structural model of rho based on the F(1) ATPase. <i>Journal of Molecular Biology</i> , 2000 , 302, 565-79	6.5	11